MDXG - MiMedx Group, Inc. Stock Price, Fair Value and News

7.80USD-0.09 (-1.14%)Market Closed

Market Summary

USD7.80-0.09

Market Closed

-1.14%

MDXG Alerts

Big jump in Earnings (Y/Y)

MDXG Stock Price

View Fullscreen

MDXG RSI Chart

MDXG Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

15.89

Price/Sales (Trailing)

3.44

EV/EBITDA

27.1

Price/Free Cashflow

33.07

MDXG Price/Sales (Trailing)

MDXG Profitability

EBT Margin

13.59%

Return on Equity

46.54%

Return on Assets

32.69%

Free Cashflow Yield

3.02%

MDXG Fundamentals

MDXG Revenue

Revenue (TTM)

334.5M

Rev. Growth (Yr)

18.18%

Rev. Growth (Qtr)

-2.44%

MDXG Earnings

Earnings (TTM)

72.5M

Earnings Growth (Yr)

285.85%

Earnings Growth (Qtr)

-82.68%

Breaking Down MDXG Revenue

Last 7 days

4.7%

Last 30 days

23.2%

Last 90 days

-3.2%

Trailing 12 Months

38.5%

How does MDXG drawdown profile look like?

MDXG Financial Health

Current Ratio

3.29

Debt/Equity

0.12

Debt/Cashflow

1.99

MDXG Investor Care

Shares Dilution (1Y)

27.68%

Diluted EPS (TTM)

0.49

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	334.5M	0	0	0
2023	280.6M	295.0M	309.0M	321.5M
2022	240.9M	239.7M	244.3M	267.8M
2021	246.5M	261.0M	259.8M	242.0M
2020	294.4M	280.6M	256.1M	248.2M
2019	341.5M	313.5M	315.4M	299.3M
2018	336.5M	351.4M	354.4M	359.1M
2017	260.4M	283.6M	303.2M	321.1M
2016	199.9M	211.6M	227.0M	245.0M
2015	139.4M	159.5M	175.0M	187.3M
2014	67.2M	79.2M	96.6M	118.2M
2013	34.9M	43.5M	51.7M	59.2M
2012	10.4M	13.4M	19.2M	27.1M
2011	2.5M	4.3M	6.0M	7.8M
2010	0	0	0	788.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MiMedx Group, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	hulse william frank iv	sold (taxes)	-64,051	7.2	-8,896	general counsel and cao
Apr 23, 2024	hulse william frank iv	sold (taxes)	-57,913	6.51	-8,896	general counsel and cao
Apr 08, 2024	hulse william frank iv	sold (taxes)	-61,382	6.9	-8,896	general counsel and cao
Mar 13, 2024	hulse william frank iv	sold	-162,029	7.95	-20,381	general counsel and cao
Mar 04, 2024	hulse william frank iv	sold (taxes)	-126,799	8.26	-15,351	general counsel and cao
Mar 01, 2024	hulse william frank iv	acquired	-	-	59,127	general counsel and cao
Mar 01, 2024	doug rice	acquired	-	-	58,478	chief financial officer
Mar 01, 2024	whitlow ricci s	acquired	-	-	58,478	chief operating officer
Feb 20, 2024	whitlow ricci s	sold	-122,351	8.012	-15,271	chief operating officer
Feb 16, 2024	whitlow ricci s	sold	-125,075	8.073	-15,493	chief operating officer

Which funds bought or sold MDXG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	SkyView Investment Advisors, LLC	new	-	77,000	77,000	0.01%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-5.05	-107,889	540,548	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.64	-174,682	898,898	-%
May 16, 2024	COMERICA BANK	reduced	-8.18	-1,538	6,399	-%
May 15, 2024	DISCIPLINED GROWTH INVESTORS INC /MN	added	11.33	-62,346	2,709,810	0.05%
May 15, 2024	AlTi Global, Inc.	reduced	-1.61	-135,342	858,966	0.02%
May 15, 2024	Engineers Gate Manager LP	added	190	464,203	764,233	0.02%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-97.03	-133,996	3,588	-%
May 15, 2024	Mariner, LLC	new	-	91,368	91,368	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	28.78	556,101	4,811,630	-%

Are Funds Buying or Selling MDXG?

Are funds buying MDXG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MDXG

No. of Funds

MDXG Alerts

Big jump in Earnings (Y/Y)

Unveiling MiMedx Group, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.64%	6,567,254	SC 13G/A
Jan 25, 2024	blackrock inc.	8.2%	9,533,518	SC 13G/A
Dec 27, 2023	falcon fund 2 holding company, l.p.	19.3%	28,195,249	SC 13D/A
Feb 09, 2023	vanguard group inc	5.36%	6,094,595	SC 13G
Feb 01, 2023	blackrock inc.	6.8%	7,781,521	SC 13G/A
Jun 15, 2022	prescience investment group llc	5.0%	5,719,888	SC 13G
May 09, 2022	prescience investment group llc	5.0%	5,719,888	SC 13D/A
Apr 28, 2022	prescience investment group llc	5.0%	5,719,888	SC 13D
Feb 08, 2022	prescience investment group llc	5.5%	6,119,888	SC 13G/A
Feb 04, 2022	blackrock inc.	6.5%	7,276,373	SC 13G

Recent SEC filings of MiMedx Group, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	4	Insider Trading
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 24, 2024	4	Insider Trading
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 10, 2024	4	Insider Trading
Mar 27, 2024	8-K	Current Report
Mar 18, 2024	3	Insider Trading
Mar 18, 2024	3	Insider Trading

Peers (Alternatives to MiMedx Group, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MiMedx Group, Inc. News

Latest updates

MiMedx Group, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-2.4%	84,709,000	86,832,000	81,712,000	81,257,000	71,676,000	74,375,000	67,689,000	66,883,000	58,894,000	50,813,000	63,074,000	68,165,000	59,967,000	68,548,000	64,303,000	53,647,000	61,736,000	76,400,000	88,863,000	67,437,000	66,555,000
Gross Profit	-1.7%	71,722,000	72,990,000	66,922,000	67,674,000	59,257,000	60,006,000	55,501,000	55,060,000	48,958,000	43,715,000	52,945,000	55,405,000	50,326,000	57,730,000	54,014,000	45,449,000	51,711,000	63,691,000	75,658,000	57,688,000	59,137,000
S&GA Expenses	1.4%	55,129,000	54,364,500	52,571,000	51,925,000	52,250,000	49,835,000	53,475,000	55,793,000	49,570,000	49,554,500	46,289,000	53,599,000	45,404,000	48,705,500	48,046,000	37,329,000	46,942,000	45,444,000	51,258,000	50,641,000	50,862,000
R&D Expenses	171.1%	2,841,000	-3,997,000	3,175,000	8,497,000	3,484,000	-4,728,000	5,953,000	5,512,000	5,964,000	-2,838,000	4,368,000	4,063,000	4,339,000	3,434,000	3,372,000	2,259,000	2,650,000	2,719,000	2,691,000	2,828,000	2,902,000
EBITDA Margin	40.2%	0.12	0.09	0.04	-0.02	-0.06	-0.08	-0.13	-0.10	-0.06	-0.05	-0.12	-0.18	-	-	-	-	-	-	-	-	-
Interest Expenses	-6.1%	-1,690,000	-1,593,500	-1,680,000	-1,630,000	-1,553,000	-1,450,000	-1,270,000	-1,170,000	-1,126,000	-1,174,000	-963,000	-1,371,000	-1,472,000	-1,508,000	-1,472,000	-2,574,000	-2,387,000	-2,395,000	-2,255,000	-269,000	211,000
Income Taxes	106.3%	2,348,000	-37,374,500	591,000	-74,000	51,000	28,000	53,000	62,000	63,000	-107,500	301,000	-5,000	58,000	-1,020,000	38,000	27,000	-11,304,000	220,000	-309,000	42,000	42,000
Earnings Before Taxes	-52.0%	11,409,000	23,793,000	9,125,000	1,126,000	-1,891,000	9,858,000	-8,373,000	-10,806,000	-10,426,000	91,500	-2,038,000	-1,784,000	-8,324,000	-17,600,000	-19,379,000	-8,439,000	-16,125,000	-7,256,000	12,070,000	-17,168,000	-13,231,000
EBT Margin	35.9%	0.14	0.10	0.05	-0.01	-0.05	-0.07	-0.12	-0.10	-0.06	-0.05	-0.11	-0.18	-	-	-	-	-	-	-	-	-
Net Income	-82.7%	9,261,000	53,477,000	8,534,000	1,200,000	-4,983,000	-414,000	-8,426,000	-10,868,000	-10,489,000	2,215,000	-2,339,000	-1,779,000	-8,382,000	-16,580,000	-19,417,000	-8,466,000	-4,821,000	-7,476,000	12,379,000	-17,210,000	-13,273,000
Net Income Margin	19.6%	0.22	0.18	0.01	-0.04	-0.09	-0.11	-0.11	-0.09	-0.05	-0.04	-0.11	-0.18	-	-	-	-	-	-	-	-	-
Free Cashflow	-43.5%	5,551,000	9,830,000	12,163,000	7,476,000	-4,681,000	-6,291,000	610,000	-3,385,000	-10,341,000	-3,557,000	5,783,000	1,194,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.3%	222	239	189	176	168	171	173	169	174	188	181	187	191	202	213	151	159	167	179	170	107
Current Assets	-15.5%	139	164	155	141	132	134	136	131	136	149	142	148	150	161	171	108	116	123	134	123	57.00
Cash Equivalents	-40.9%	48.00	82.00	81.00	69.00	61.00	66.00	73.00	73.00	76.00	87.00	91.00	85.00	85.00	96.00	110	48.00	54.00	69.00	94.00	97.00	28.00
Inventory	16.3%	24.00	21.00	19.00	17.00	15.00	13.00	14.00	13.00	13.00	11.00	11.00	10.00	12.00	10.00	11.00	11.00	9.00	9.00	12.00	15.00	16.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	11.00	11.00	10.00	11.00	12.00	12.00	13.00	15.00	16.00
Goodwill	0%	19.00	19.00	19.00	19.00	20.00	19.00	20.00	20.00	20.00	19.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00	20.00
Liabilities	-31.5%	66.00	96.00	95.00	97.00	94.00	97.00	100	90.00	89.00	95.00	94.00	102	107	111	109	128	129	133	140	146	69.00
Current Liabilities	-8.2%	42.00	46.00	44.00	44.00	41.00	44.00	46.00	37.00	37.00	42.00	42.00	51.00	55.00	59.00	57.00	64.00	64.00	67.00	73.00	78.00	64.00
Long Term Debt	-61.6%	18.00	48.00	49.00	49.00	49.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	61.00	62.00	62.00	62.00	63.00	-
LT Debt, Current	0%	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	4.00	4.00	4.00	4.00	-
LT Debt, Non Current	-61.6%	18.00	48.00	49.00	49.00	49.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	61.00	62.00	62.00	62.00	63.00	-
Shareholder's Equity	9.1%	156	143	1.00	-	-17.95	-17.99	-	-	-	0.00	-	-	-	-	13.00	23.00	30.00	34.00	40.00	25.00	38.00
Retained Earnings	6.9%	-124	-133	-187	-195	-196	-191	-191	-183	-172	-161	-163	-161	-159	-151	-134	-115	-106	-102	-94.66	-107	-89.83
Additional Paid-In Capital	1.4%	280	276	188	183	179	174	172	169	165	166	162	159	157	159	158	152	150	147	144	136	166
Shares Outstanding	0.9%	148	146	116	116	114	114	113	113	112	110	111	110	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	760	-	-	-	388	-	-	-	1,381	-	-	-	538	-	-	-	425	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-41.7%	5,978	10,257	12,791	7,775	-4,048	-5,624	959	-3,005	-10,223	-3,232	6,330	1,599	-6,679	-10,267	-4,618	-3,097	-12,281	-23,122	-3,160	2,130	-15,260
Share Based Compensation	-1.1%	4,340	4,387	4,388	4,060	3,904	530	2,372	4,428	3,998	3,041	3,811	4,060	3,244	3,905	3,669	4,434	3,349	2,865	2,686	3,499	3,014
Cashflow From Investing	-1152.4%	-6,024	-481	-649	-348	-677	-1,709	-374	-429	-148	-314	-580	-422	-2,079	-2,273	-710	-486	-1,086	-793	2,060	-330	-433
Cashflow From Financing	-274.4%	-33,467	-8,940	370	4.00	-4.00	66.00	130	260	-1,036	22.00	-150	-916	-2,308	-1,243	66,734	-1,753	-2,177	-1,138	-1,707	66,748	-1,044
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MDXG Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 84,709	$ 71,676
Cost of sales	12,987	12,419
Gross profit	71,722	59,257
Operating expenses:
Selling, general and administrative	55,129	52,250
Research and development	2,841	3,484
Investigation, restatement and related	311	3,673
Amortization of intangible assets	189	190
Impairment of intangible assets	54	0
Operating income (loss)	13,198	(340)
Other expense, net
Interest expense, net	(1,690)	(1,553)
Other (expense) income, net	(99)	2
Income (loss) from continuing operations before income tax	11,409	(1,891)
Income tax expense from continuing operations	(2,348)	(51)
Net income (loss) from continuing operations	9,061	(1,942)
Income (loss) from discontinued operations, net of tax	200	(3,041)
Net income (loss)	9,261	(4,983)
Net income (loss) from continuing operations available to common stockholders	$ 9,061	$ (3,626)
Basic net income (loss) per common share:
Continuing operations - basic (in dollars per share)	$ 0.06	$ (0.03)
Discontinued operations - basic (in dollars per share)	0	(0.03)
Basic net income (loss) per common share (in dollars per share)	0.06	(0.06)
Diluted net income (loss) per common share:
Continuing operations- diluted(in dollars per share)	0.06	(0.03)
Discontinued operations- diluted (in dollars per share)	0	(0.03)
Diluted net (loss) income per common share (in dollars per share)	$ 0.06	$ (0.06)
Weighted average common shares outstanding - basic (in shares)	146,404,587	114,398,813
Weighted average shares outstanding - diluted (in shares)	150,028,107	114,398,813

MDXG Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 48,487	$ 82,000
Accounts receivable, net	57,016	53,871
Inventory	24,454	21,021
Prepaid expenses	6,095	5,624
Other current assets	2,801	1,745
Total current assets	138,853	164,261
Property and equipment, net	7,340	6,974
Right of use asset	3,499	2,132
Deferred tax asset, net	38,747	40,777
Goodwill	19,441	19,441
Intangible assets, net	12,550	5,257
Other assets	1,251	205
Total assets	221,681	239,047
Current liabilities:
Current portion of long term debt	1,000	1,000
Accounts payable	9,697	9,048
Accrued compensation	17,913	22,353
Accrued expenses	9,196	9,361
Current liabilities of discontinued operations	344	1,352
Other current liabilities	4,071	2,894
Total current liabilities	42,221	46,008
Long term debt, net	18,453	48,099
Other liabilities	5,276	2,223
Total liabilities	65,950	96,330
Commitments and contingencies (Note 12)
Stockholders' equity
Common stock; $0.001 par value; 250,000,000 shares authorized; 147,528,596 issued and outstanding at March 31, 2024 and 146,227,639 issued and outstanding at December 31, 2023	148	146
Additional paid-in capital	280,000	276,249
Accumulated deficit	(124,417)	(133,678)
Total stockholders' equity	155,731	142,717
Total liabilities and stockholders’ equity	$ 221,681	$ 239,047

About MiMedx Group, Inc.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

CEO	Mr. Joseph H. Capper
WEBSITE	mimedx.com
INDUSTRY	Biotechnology
EMPLOYEES	867

MiMedx Group, Inc. Frequently Asked Questions

What is the ticker symbol for MiMedx Group, Inc.? What does MDXG stand for in stocks?

MDXG is the stock ticker symbol of MiMedx Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MiMedx Group, Inc. (MDXG)?

As of Fri May 17 2024, market cap of MiMedx Group, Inc. is 1.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MDXG stock?

You can check MDXG's fair value in chart for subscribers.

What is the fair value of MDXG stock?

You can check MDXG's fair value in chart for subscribers. The fair value of MiMedx Group, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MiMedx Group, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MDXG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MiMedx Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether MDXG is over valued or under valued. Whether MiMedx Group, Inc. is cheap or expensive depends on the assumptions which impact MiMedx Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MDXG.

What is MiMedx Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MDXG's PE ratio (Price to Earnings) is 15.89 and Price to Sales (PS) ratio is 3.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MDXG PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MiMedx Group, Inc.'s stock?

In the past 10 years, MiMedx Group, Inc. has provided 0.038 (multiply by 100 for percentage) rate of return.